Skip to main content
Log in

Salivary testosterone is associated with higher lumbar bone mass in premenopausal healthy women with normal levels of serum testosterone

  • Published:
European Journal of Epidemiology Aims and scope Submit manuscript

Abstract

The relationships among lumbar and femoral bone mineral density (BMD) and different forms of testosterone -total, salivary testosterone and free testosterone index (FTI) calculated with the sex hormone binding globulin (SHBG)-, body mass index (BMI) and body fat distribution (waist-to-hip ratio and breast-to-hip ratio) were analysed in a cross-sectional study with 66 Spanish premenopausal healthy women aged 42 years and with normal levels of serum testosterone. BMD was measured using dual-energy X-ray absorptiometry (Hologic QDR 1000 ®), and salivary and blood samples were obtained during early follicular phase. In a multiple stepwise regression analysis, lumbar BMD was positively predicted by salivary testosterone and negatively by SHBG adjusted by BMI (R 2 = 0.20; p < 0.02). The most femoral BMDs were negatively predicted by SHBG and positively by breast-to-hip ratio (R 2 = 0.22–0.33, according to the site measured), but neck BMD was not predicted by any variable. When FTI was entered into the regression model instead of SHBG, it was not an independent predictor of BMD. The waist-to-hip ratio was positively correlated with several femoral BMD sites, but breast-to-hip ratio was better predictor. After adjusting by SHBG, the BMI was only predictor for intertrochanter BMD. All women with elevated salivary testosterone (n = 12) had higher lumbar BMD than those with normal value (1.120 ± 0.112 vs. 1.026 ± 0.118; p < 0.01) without differences in other confounding variables. As a conclusion, in premenopausal healthy women of the same age with normal levels of serum testosterone, low levels of SHBG and high levels of salivary testosterone are associated with higher lumbar BMD, whereas low levels of SHBG together with higher breast-to-hip ratio are associated with higher femoral BMD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Haffner SM, Bauer RL. Excess androgenicity only partially explains the relationship between obesity and bone density in premenopausal women. Int J Obes 1992; 16: 869–874.

    Google Scholar 

  2. Orozco P, Nolla JM. Association between body morphology and bone mineral density in premenopausal women. Eur J Epidemiol 1997; 17: 919–924.

    Google Scholar 

  3. Aloia JF, Cohn SH, Vaswani A, Yeh JK, Yuen K, Ellis K. Risk factors for postmenopausal osteoporosis. Am J Med 1985; 78: 95–100.

    Google Scholar 

  4. Sowers MFR, Galuska DA. Epidemiology of bone mass in premenopausal women. Epidemiol Rev 1993; 15: 373–398.

    Google Scholar 

  5. Simberg N, Tiitinen A, Silfvast A, Viinikka L, Ylikorkala O. High bone density in hyperandrogenic women: Effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement. J Clin Endocrinol Metab 1996; 81: 646–651.

    PubMed  Google Scholar 

  6. Adami S, Zamberlan N, Castello R, Tosi F, Gatti D, Moghetti P. Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clin Endocrinol (oxf) 1998; 48: 169–173.

    Google Scholar 

  7. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995; 21: 227–236.

    PubMed  Google Scholar 

  8. Garnett T, Studd J, Watson N, Savvas M, Leather A. The effects of plasma estradiol levels on increases in vertebral and femoral bone density following therapy with estradiol and estradiol with testosterone implants. Obstet Gynecol 1992; 79: 968–972.

    PubMed  Google Scholar 

  9. Savvas M, Studd JW, Norman S, Leather AT, Garnett TJ, Fogelman I. Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post-menopausal women who have previously received long-term oral oestrogens. Br J Obstet Gynaecol 1992; 99: 757–760.

    PubMed  Google Scholar 

  10. Riad-Fahmy D, Read GF, Walker RF, Griffiths K. Steroids in saliva for assessing endocrine function. Endocr Rev 1982; 3: 367–395.

    PubMed  Google Scholar 

  11. Blom T, Ojanotki-Harri A, Laine M, Huhtaniemi I. Metabolism of progesterone and testosterone in human parotid and submandibular salivary glands in vitro. J Steroid Biochem Mol Biol 1993; 44: 69–76.

    PubMed  Google Scholar 

  12. Swinkel LM, Meulenberg PM, Ross HA, Benraad TJ. Salivary and plasma free testosterone and androstenedione levels in women using contraceptives containing desogestrel or levonorgestrel. Ann Clin Biochem 1988; 25: 354–359.

    PubMed  Google Scholar 

  13. Navarro MA, Nolla JM, Machuca MI, et al. Salivary testosterone in postmenopausal women with rheumatoid arthritis. J Rheumatol 1998; 25: 1059–1062.

    PubMed  Google Scholar 

  14. Osredkar J, Vrhovee I, Jesenovee N, Kocijancic A, Prezelj J. Salivary free testosterone in hirsutism. Ann Clin Biochem 1989; 26: 522–526.

    PubMed  Google Scholar 

  15. Rey F, Chiodoni G, Gomez F, Felber JP. Interpretation of the discrepancy observed between plasma and salivary testosterone levels in man. Steroids 1988; 52: 371–372.

    PubMed  Google Scholar 

  16. Steinberg KK, Freni-Titulaer LW, DePuey EC, et al. Sex steroids and bone density in premenopausal women. J Clin Endocrinol 1989; 69: 533–539.

    Google Scholar 

  17. Reid IR, Ames R, Evans MC, et al. Determinants of total body and regional bone mineral density in normal postmenopausal women-a key role for fat mass. J Clin Endocrinol Metab 1992; 75: 45–51.

    PubMed  Google Scholar 

  18. Daniel M, Martin AD, Drinkwater DT. Cigarette smoking, steroid hormones, and bone mineral density in young women. Calcif Tissue Int 1992; 50: 300–305.

    PubMed  Google Scholar 

  19. Slemenda C, Longcope C, Peacock M, Hui S, Johnston C. Sex steroid, bone mass, and bone loss. A prospective study of pre-, peri, and postmenopausal women. J Clin Invest 1996; 97: 14–21.

    PubMed  Google Scholar 

  20. Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of osteoporotic fractures research group. N Eng J Med 1998; 10: 733–738.

    Google Scholar 

  21. Stone K, Bauer DC, Black DM, Sklarin P, Ensrud KE, Cummings SR. Hormonal predictors of bone loss in elderly women: A prospective study. The study of osteoporotic fractures research group. J Bone Miner Res 1998; 13: 1167–1174.

    PubMed  Google Scholar 

  22. Ortego-Centeno N, Muñoz-Torres M, Hernandez-Quero J, Jurado-Duce A, de la Higuera Torres-Puchol J. Bone mineral density, sex steroids, and mineral metabolism in premenopausal smokers. Calcif Tissue Int 1994; 55: 403–407.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Orozco, P., Navarro, M. & Nolla, J. Salivary testosterone is associated with higher lumbar bone mass in premenopausal healthy women with normal levels of serum testosterone. Eur J Epidemiol 16, 907–912 (2000). https://doi.org/10.1023/A:1011064606060

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011064606060

Navigation